Fenofibrate: A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes Mellitus

By Keating Gillian M.   Croom Katherine F.  

Drugs, Vol. 67, Iss. 1, 2007-01 ,pp. : 121-153

Adis International

Access to resources Recommend Favorite

Fine Tuning of PPAR Ligands for Type 2 Diabetes and Metabolic Syndrome

By  

Mini Reviews in Medicinal Chemistry, Vol. 6, Iss. 5, 2006-01 ,pp. : 563-573

Bentham Science Publishers

Access to resources Recommend Favorite

The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes

By Nelson Robert H   Miles John M  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 14, 2005-11 ,pp. : 2483-2491

Informa Healthcare

Access to resources Recommend Favorite

The Relationship between Adipokines, Metabolic Parameters and Insulin Resistance in Patients with Metabolic Syndrome and Type 2 Diabetes

By Lee JM   Kim SR   Yoo SJ   Hong OK   Son HS   Chang SA  

The Journal of International Medical Research, Vol. 37, Iss. 6, 2009-11 ,pp. : 1803-1812

Field House Publishing

Access to resources Recommend Favorite

Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus

By Reyes-Soffer Gissette   Rondon-Clavo Carlos   Ginsberg Henry N  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 9, 2011-06 ,pp. : 1429-1438

Informa Healthcare

Access to resources Recommend Favorite